Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals With Type 1 Diabetes and Healthy Individuals

Nino Gogitidze Joy, MD1
Maka S. Hedrington, MD1
Vanessa J. Briscoe, PhD, NP2
Donna B. Tate, MS1
Andrew C. Ertl, PhD2
Stephen N. Davis, MD1,2

OBJECTIVE — Recent large randomized trials have linked adverse cardiovascular and cerebrovascular events with hypoglycemia. However, the integrated physiological and vascular biological mechanisms occurring during hypoglycemia have not been extensively examined. Therefore, the aim of this study was to determine whether 2 h of moderate clamped hypoglycemia could decrease fibrinolytic balance and activate pro-atherothrombotic mechanisms in individuals with type 1 diabetes and healthy individuals.

RESEARCH DESIGN AND METHODS — Thirty-five healthy volunteers (19 male and 16 female subjects age 32 ± 2 years, BMI 26 ± 2 kg/m², A1C 5.1 ± 0.1%) and twenty-four with type 1 diabetes (12 male and 12 female subjects age 33 ± 3 years, BMI 24 ± 2 kg/m², A1C 7.7 ± 0.2%) were studied during either a 2-h hyperinsulinemic (9 pmol·kg⁻¹·min⁻¹) euglycemic or hypoglycemic (2.9 ± 0.1 mmol/l) clamp or both protocols. Plasma glucose levels were normalized overnight in type 1 diabetic subjects prior to each study.

RESULTS — Insulin levels were similar (602 ± 44 pmol/l) in all four protocols. Glycemia was equivalent in both euglycemic protocols (5.2 ± 0.1 mmol/l), and the level of hypoglycemia was also equivalent in both type 1 diabetic subjects and healthy control subjects (2.9 ± 0.1 mmol/l). Using repeated ANOVA, it was determined that plasminogen activator inhibitor (PAI-1), vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), E-selectin, P-selectin, interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and adiponectin responses were all significantly increased ($P < 0.05$) during the 2 h of hyperinsulinemic hypoglycemia as compared with euglycemia in healthy control subjects. All measures except PAI-1 were also found to be increased during hypoglycemia compared with euglycemia in type 1 diabetes.

CONCLUSIONS — In summary, moderate hypoglycemia acutely increases circulating levels of PAI-1, VEGF, vascular adhesion molecules (VCAM, ICAM, E-selectin), IL-6, and markers of platelet activation (P-selectin) in individuals with type 1 diabetes and healthy individuals. We conclude that acute hypoglycemia can result in complex vascular effects including activation of prothrombotic, proinflammatory, and pro-atherogenic mechanisms in individuals with type 1 diabetes and healthy individuals.

From the 1University of Maryland School of Medicine, Baltimore, Maryland; and the 2Department of Diabetes, Endocrinology, and Metabolism, Vanderbilt University, Nashville, Tennessee.

Corresponding author: Stephen N. Davis, sdavis@medicine.umaryland.edu.

Received 23 February 2009 and accepted 15 March 2010. DOI: 10.2337/dc09-0354. Clinical trial reg. no. NCT00574340, clinicaltrials.gov.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

See accompanying original article, p. 1591, and editorial, p. 1686.
values could be controlled independently during each study.

**RESEARCH DESIGN AND METHODS** — Thirty-five healthy subjects (19 male and 16 female subjects, age 32 years ± 2, BMI 26 ± 2 kg/m², A1C 5.1 ± 0.1) and twenty-four with type 1 diabetes (12 male and 12 female subjects, age 33 ± 3 years, BMI 24 ± 2 kg/m², A1C 7.7 ± 0.2 [normal range 4–6.5%]), diabetes duration 17 ± 8 years) were studied (data can be found in online appendix Table 1, available at http://care.diabetesjournals.org/cgi/content/full/dc09-0354/DC1). Individuals with type 1 diabetes had normal bedside tests of autonomic function (12) and did not have hypoglycemia unawareness based on the methods of Gold, et al. (13). Type 1 diabetic individuals had no major macro or micro complications of diabetes. Type 1 diabetic subjects were excluded from the study if they had a history of hypoglycemia induced convulsions or a major episode of hypoglycemia in the preceding 2 years. Type 1 diabetes individuals were treated with multiple daily insulin injections or with an insulin pump. All subjects were nonsmokers and had a normal blood count, plasma lipids, plasma electrolytes, liver, and renal function, and were normotensive. No subject was taking medications known to affect neuroendocrine responses to hypoglycemia (specifically, fluoxetine) or influence platelet, clotting, or fibrinolytic balance. Some of the individuals included in the present study had served as control subjects to determine usual baseline counterregulatory responses to hypoglycemia in previous studies (14,15). Studies were approved by the Vanderbilt University human subjects Institutional Review Board, and all participants gave written informed consent.

Subjects participated in either a single hyperinsulinemic euglycemic or hypoglycemic clamp or both sets of experiments. The number of individuals participating in each arm of the study were: type 1 diabates euglycemia (n = 14), type 1 diabetes hypoglycemia (n = 17), healthy control euglycemia (n = 22), healthy control hypoglycemia (n = 25). Ten healthy control subjects and seven individuals with type 1 diabetes participated in both euglycemic and hypoglycemic protocols in a randomized fashion. Results from this subgroup are conceptually similar to the entire cohort (data are available in online appendix Table 3, Fig. A1 and A2). All study patients were asked to avoid any exercise and consume their usual weight-maintaining diet for 3 days before each experiment. All type 1 diabetic patients were asked to perform intensive home blood glucose monitoring (i.e., at least four glucose tests per day) and to avoid hypoglycemia for at least 5 days before a study. On the day prior to a study, intermediate or long-acting insulin was discontinued and replaced by injections of regular insulin before breakfast and lunch. Each subject was admitted to the Vanderbilt General Clinical Research Center (VCR) at ~5:00 P.M. the evening before an experiment. At this time in the individuals with type 1 diabetes, two intravenous cannulae were inserted under 1% lidocaine local anesthesia. One cannula was placed in a retrograde fashion into a vein on the back of the hand. This hand was placed in a heated box (55–60°C) during the study so that arterialized blood could be obtained. The other cannula was placed in the contralateral arm for infusions. All subjects received an evening meal, and individuals with type 1 diabetes received a continuous low-dose infusion of insulin to normalize plasma glucose. The insulin infusion was adjusted overnight to maintain blood glucose between 4.4 and 7.2 mmol/l.

**Hypoglycemia experiments**

All subjects were studied after an overnight, 10-h fast. Venous cannulae as described above were placed in the healthy control subjects. After this, a period of 120 min was allowed to elapse followed by a 120-min hyperinsulinemic hypoglycemic experimental period. At time 120 min, a primed constant (9.0 pmol·kg⁻¹·min⁻¹) infusion of insulin (Human Regular Insulin; Eli Lilly, Indianapolis, IN) was started and continued until 240 min. The rate of fall of glucose was controlled (~0.08 mmol/min), and the glucose nadir (2.9 mmol/l) was achieved using a modification of the glucose clamp technique. During the clamp period, plasma glucose was measured every 5 min and a 20% dextrose infusion was adjusted so that plasma glucose levels were held constant at 2.9 ± 0.1 mmol/l (16). Potassium chloride (20 mmol/l) was infused during the clamp to reduce insulin-induced hypokalemia.

**Euglycemia experiments**

These experiments followed the same format as the above described hypoglycemia experiments with the exception that euglycemia (5.2 ± 0.1 mmol/l) was maintained during each study.

**Analytical methods**

The collection of blood samples has been described elsewhere (14). Plasma glucose concentrations were measured in triplicate using the glucose oxidase method with a glucose analyzer (Beckman, Fullerton, CA). Insulin was measured as previously described with an interassay coefficient of variation (CV) of 9% (14). Catecholamines were determined by high-performance liquid chromatography with an interassay CV of 12% for epinephrine and 8% for norepinephrine (14). Cortisol was assayed using the clinical assays γ-coat radioimmunoassay kit with an interassay CV of 6% (14). Nonesterified fatty acids (NEFAs) were measured using the WAKO kit with an interassay CV of 7%.

Blood was drawn every 60 min for soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), E-selectin, P-selectin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), and adiponectin was drawn every 60 min and every 30 min for catecholamines, cortisol, and NEFA during the experimental period. Vascular adhesion molecules and adiponectin were assayed using LINCO Research Kits (St. Charles, Missouri) with interassay CVs of 8.5% for sVCAM, 9.7% for sICAM, 13.4% for E-selectin, 15.9% for adiponectin, 9.02% for IL-6, 9.98% for TNF-α, and 8.2% for VEGF. P-selectin (CV 9.9%). Meso scale discovery (Gaithersburg, MD), PAI-1, and tPA antigen were determined by TintElize PAI-1 Kit with interassay CV of 3.3%.

**Statistical analysis**

Data are expressed as means ± SE and were analyzed using standard, parametric, one and two-way analysis of variance (ANOVA) with repeated measures where appropriate (SPSS, Chicago, IL). Data were also analyzed with paired and unpaired two tailed t test (Graph Pad Software, San Diego, CA). In all cases, a P < 0.05 was accepted as statistically significant. Individual peak and nadir values during the final 60 min (at time 180 or 240 min) of hypoglycemia and euglycemia were compared for vascular biological parameters.
Glucose and insulin
Plasma glucose was maintained equivalently (5.2 ± 0.1 mmol/l) during the euglycemic clamps. Plasma glucose reached steady state by 150 min, and equivalent hypoglycemia (2.9 ± 0.1 mmol/l) was maintained during all hypoglycemia clamp procedures (online appendix Fig. A3). Insulin levels (602 ± 24 pmol/l) for both healthy and type 1 diabetes groups were similar during all four protocol clamp studies (online appendix Fig. A3).

Neuroendocrine counterregulatory hormones
Epinephrine responses were significantly higher (P < 0.001) during the final 30 min of hypoglycemia (5.6 ± 0.7 nmol/l, 3.14 ± 0.5 nmol/l) as compared with euglycemia (0.19 ± 0.03 nmol/l, 0.27 ± 0.04 nmol/l) in both the healthy and type 1 diabetic groups, respectively. Epinephrine values were higher during hypoglycemia in healthy control subjects (P = 0.008) as compared with type 1 diabetic subjects. Norepinephrine levels were also significantly higher (P < 0.001) during the final 30 min of hypoglycemia (1.9 ± 0.3 nmol/l, 1.8 ± 0.02 nmol/l) as compared with euglycemia (0.9 ± 0.2 nmol/l, 1.1 ± 0.01 nmol/l) in healthy control subjects and type 1 diabetic subjects, respectively. Norepinephrine levels were not different during hypoglycemia in healthy control subjects and type 1 diabetic subjects. There was a trend for plasma cortisol levels to be higher in healthy control subjects as compared with type 1 diabetic subjects (861 ± 42 vs. 725 ± 46 nmol/l, P = 0.09). Cortisol values were higher (P < 0.001) during hypoglycemia as compared with euglycemia in both healthy control subjects (861 ± 42 vs. 357 ± 24 nmol/l) and type 1 diabetic subjects (725 ± 46 vs. 302 ± 66 nmol/l), respectively.

Intermediary metabolism
Blood NEFA levels fell significantly (P < 0.0001) during hypoglycemic and euglycemic clamps. However, there were significantly higher levels (P < 0.05) of NEFA during the final 30 min of hypoglycemia as compared with euglycemia in both healthy control subjects (97 ± 11 vs. 68 ± 18 μmol/l) and type 1 diabetic patients (100 ± 18 vs. 50 ± 4 μmol/l), respectively.

Atherogenic vascular adhesion molecules
With the exception of VCAM-1 in healthy control subjects and ICAM-1 in subjects with type 1 diabetes, baseline values were similar at the start of euglycemic and hypoglycemic clamps (online appendix Tables 2 and 3). Plasma VCAM, ICAM, and E-selectin responses during the 120-min clamp studies were significantly different (P < 0.05–P < 0.0001 ANOVA) during hypoglycemia as compared with euglycemia in both healthy control subjects and type 1 diabetic subjects. Statistical difference with two-way ANOVA during the 120-min clamp experiments is marked in each graph panel.
from baseline ($P < 0.05$) during hypoglycemia (Fig. 3); mean individual nadir values of VCAM, ICAM, and E-selectin were significantly ($P < 0.05$) decreased from baseline during euglycemia in both type 1 diabetic subjects and healthy control subjects (Fig. 3). The magnitude of responses did not differ in healthy control subjects and type 1 diabetic subjects.

**Platelet activation and fibrinolytic balance**

Plasma P-selectin responses were significantly different ($P < 0.05$ ANOVA) during the hypoglycemic as compared with euglycemic clamp studies in both healthy control subjects and type 1 diabetic subjects (Fig. 2). Baseline PAI-1 levels were significantly different ($P < 0.05$) in the type 1 diabetes group (online appendix Table 3). Plasma PAI-1 values were significantly different during hypoglycemia as compared with euglycemia in healthy control subjects but not type 1 diabetic subjects (Fig. 2). Mean individual peak values from baseline for P-selectin and PAI-1 responses were increased ($P < 0.05$) during hypoglycemia in both healthy control subjects and type 1 diabetic subjects (Fig. 3). Nadir P-selectin and PAI-1 values were significantly ($P < 0.01$) lower from baseline during hyperinsulinemic euglycemia in both type 1 diabetic subjects and healthy control subjects (Fig. 3). Plasma concentrations of tPA did not alter during either euglycemic or hypoglycemic clamps in both normal subjects and individuals with type 1 diabetes. Responses of P-selectin, tPA and PAI-1 were similar in healthy control subjects and type 1 diabetic subjects.

**Adiponectin, VEGF, and inflammatory cytokines**

Baseline values for adiponectin, VEGF, IL-6, and TNF-α were similar at the start of both sets of glucose clamps (online appendix Tables 2 and 3). Plasma adiponectin responses were significantly different ($P < 0.01$ ANOVA) during the 120-min hypoglycemic and euglycemic clamps in healthy control subjects and type 1 diabetic subjects (Fig. 3). Mean individual nadir values for adiponectin were significantly ($P < 0.05$) reduced from baseline during hyperinsulinemic euglycemia in both subjects with type 1 diabetes and healthy control subjects (Fig. 3). There was a trend ($P = 0.06$ ANOVA) for peak adiponectin levels to increase from baseline during hypoglycemia in type 1 diabetic subjects (Fig. 3). VEGF and IL-6 responses were significantly different ($P < 0.04$–$P = 0.0004$ ANOVA) during hypoglycemia and euglycemia in type 1 diabetic subjects and healthy control subjects (Figs. 1 and 2). Nadir values for VEGF and IL-6 were significantly decreased ($P < 0.04$–$P < 0.01$) from baseline during hyperinsulinemic euglycemia in both subjects with type 1 diabetes and healthy control subjects (Fig. 3). Mean individual peak values during hypoglycemia were increased from baseline ($P < 0.05$) in both type 1 diabetic subjects and healthy control subjects. Peak values for TNF-α in-
creased from baseline (P < 0.05) during hypoglycemia in type 1 diabetic subjects and nadir values were also significantly decreased (P < 0.05) from baseline during hyperinsulinemic euglycemia in healthy control subjects. Adiponectin, VEGF, TNF-α and IL-6 responded similarly during hypoglycemia in healthy control subjects and type 1 diabetic subjects (Fig. 3).

CONCLUSIONS — This study has determined the effects of 2 h of clamped hyperinsulinemic euglycemia and moderately hyperglycemia on proinflammatory mechanisms and fibrinolytic balance in individuals with type 1 diabetes and healthy individuals. Our results demonstrate that hypoglycemia can have acute and widespread effects on vascular biology. Hypoglycemia can 1) activate proinflammatory mechanisms (ICAM, VCAM, E-selectin, VEGF, IL-6), 2) increase platelet activation (P-selectin), and 3) simultaneously decrease systemic fibrinolytic balance (increase in PAI-1, no change in tPA) in both individuals type 1 diabetes and healthy individuals. These effects were of a similar magnitude in the healthy control subjects and type 1 diabetic subjects and were in contrast to the reduced responses of the above vascular biological mechanisms that occurred during clamped euglycemia with equivalent hyperinsulinemia.

In this present study, the effects of hypoglycemia and hyperinsulinemia on different proinflammatory and potentially pro-atherothrombotic mechanisms have been determined. ICAM-1, VCAM-1 and E-selectin are cell surface proteins that are upregulated during inflammation and increase the adhesion of leukocytes to injured arterial endothelial cells, which is a primary step in plaque formation and subsequent atherosclerosis. Analysis of the responses during the hyperinsulinemic clamps demonstrates a significant effect of hypoglycemia to increase VCAM, ICAM, E-selectin, and VEGF relative to euglycemia in both healthy control subjects and type 1 diabetic subjects individually. VEGF has been reported to be pro-atherosclerotic in animals (17). In addition, VEGF can potentely increase proliferation of the endothelium leading to new blood vessels. Hypoglycemia also had similar effects, increasing plasma levels of P-selectin in both individuals with type 1 diabetes and nondiabetic individuals. P-selectin is an adhesion molecule that is activated by inflammation (18) and is expressed by both endothelial cells and platelets. Recent work has demonstrated that platelets are the major source of P-selectin, and thus this molecule has been recognized as a significant marker of platelet activation and increased thrombotic mechanisms (18). PAI-1 was increased during hypoglycemia relative to euglycemia in healthy control subjects but not subjects with type 1 diabetes. However, individual peak values of PAI-1 were increased during hypoglycemia in both healthy control subjects and subjects with type 1 diabetes, demonstrating that hypoglycemia of 2.9 mmol/l can be a stimulus for increased values of PAI-1.

Our present results demonstrate that hypoglycemia decreases systemic fibrinolytic balance by increasing PAI-1 levels while maintaining tPA values. Thus, at least two separate mechanisms for in-
Vascular effects of hypoglycemia

Nitric oxide (NO) has also been implicated in the regulation of both endothelial and platelet-derived adhesion molecules (24). Although not specifically addressed in the present study, we have preliminary data indicating that hypoglycemia impairs endothelial NO function. We would therefore suggest that NO may also be a significant molecular mechanism involved in hypoglycemia’s vascular effects.

Adiponectin is released from adipose tissue and is known to have powerful insulin sensitizing and antiatherogenic properties. To our knowledge, adiponectin responses have not been investigated during hypoglycemia in type 1 diabetes or healthy volunteers. We were intrigued to discover that hypoglycemia also increased (relative to euglycemia) adiponectin levels in type 1 diabetic subjects and healthy control subjects. The significance of the finding is unclear and requires further study.

We would also like to indicate that in this present study, insulin, per se, had significant, beneficial effects on vascular physiology. It is notable that in every case where hypoglycemia resulted in an activation of a pathologic process, there was an equal and opposite beneficial effect during the hyperinsulinemic euglycemic control studies in both type 1 diabetes and healthy individuals. Thus, our present results would support previous work demonstrating that insulin has anti-inflammatory and antiatherogenic properties (10,21,24,25). There are some limitations to this study. There are sizeable interindividual variations in inflammatory and pro-atherothrombotic vascular biomarkers. Thus, baseline values for VCAM-1 in healthy control subjects and ICAM-1 and PAI-1 in subjects with type 1 diabetes were significantly different at the start of the euglycemic and hypoglycemic clamps. We do not know the reason for these baseline differences. One possible explanation is that not everyone in the study participated in both euglycemic and hypoglycemic clamps. We believe this is unlikely to be the case as there was also a significant difference in baseline PAI-1 values in the type 1 diabetic subjects who participated in both series of glucose clamps. The magnitude of the changes of the vascular biomarkers during hypoglycemia (and euglycemia) are relatively modest. Thus, maximal changes in vascular biomarkers during hypoglycemia of 50–75% is greatly reduced compared with the multiple fold increases of neuroendocrine hormones occurring during identical hypoglycemia. However, the ability to compare the increases of the vascular biomarkers during hyperinsulinemic hypoglycemia with the similar decreases occurring during hyperinsulinemic euglycemia does demonstrate the independent effects of hypoglycemia. The clinical significance of the magnitude of the changes in the differing proinflammatory and pro-atherothrombotic vascular biomarkers is yet to be established. We only studied one level of hypoglycemia. Thus, we cannot comment on whether deeper hypoglycemia (i.e., less than 2.9 mmol/l) would have induced greater changes in vascular biological markers. Additionally, the present study was designed to study vascular physiologic changes during prolonged hypoglycemia of 2 h. Therefore, we cannot determine the effects of shorter durations of hypoglycemia (i.e., 30–45 min) on study end points.

In summary, this present study has demonstrated the complex effects of acute moderate hypoglycemia on fibrinolytic balance and proinflammatory mechanisms in type 1 diabetic subjects and healthy control subjects. Using glucose clamps to equate insulin levels, this study has demonstrated that hypoglycemia results in significant increases in proinflammatory and potentially pro-atherogenic adhesion molecules (ICAM, VCAM, Eselectin, IL-6, VEGF) platelet activation (P-selectin), and reduced fibrinolytic balance (increased PAI-1). We conclude that 1) hypoglycemia can similarly activate a broad spectrum of vascular biological mechanisms in both type 1 diabetic subjects and age- and weight-matched non-diabetic control subjects, and 2) the potentially deleterious long-term effects of hypoglycemia on pro-atherothrombotic mechanisms needs further study.
References

1. Gold AE, Marshall SM. Cortical blindness and cerebral infarction associated with severe hypoglycaemia. Diabetes Care 1996; 19:1001–1003

2. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycaemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485–1489

3. Wei M, Gibbons LW, Mitchell TL, Kumpert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 2000;101:2047–2052

4. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559

5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McAllister V, Vitale ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139

6. Campbell I. Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia? Diabet Med 1991;8:3–4

7. Nathan DM, Cleary PA, Backlund JY, Geenuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643

8. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes/Metabolism Research and Reviews 2008;24:353–363

9. Wieczorek I, Pell AC, McIver B, MacGregor IR, Ludlam CA, Frier BM. Coagulation and fibrinolytic systems in type 1 diabetes: effects of venous occlusion and insulin induced hypoglycaemia. Clin Sci (Lond) 1993;84:79–86

10. Ibbotson SH, Catto A, Davies JA, Grant PJ. The effect of insulin-induced hypoglycaemia on factor VIII:C concentrations and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. Thromb Haemost 1995;73:243–246

11. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Effect of hyperglycaemia and insulin in acute coronary syndromes. Am J Cardiol 2007;99:12H–18H

12. Ewing DJ, Marty CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8:491–498

13. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia. Diabetes Care 1994;17:697–703

14. Briscoe VJ, Ertl AC, Tate DB, Dawling S, Davis SN. Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycaemia in healthy individuals. Diabetes 2008;57:2453–2460

15. Briscoe VJ, Ertl AC, Tate DB, Davis SN. Effects of the selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycaemia in individuals with type 1 diabetes. Diabetes 2008;57:3315–3322

16. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose counterregulation after strict, glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987;316:1376–1383

17. Cellotti FL, Waugh JM, Amabile PG, Bredolan A, Hulikfer PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;4:425–429

18. Ferroni P, Martini F, Riondino S, La Farina F, Magnapera A, Ciatti F, Guadagni F, Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta 2009;399:88–91

19. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999;84:4097–4105

20. Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E, Schino P, Tamponi G, Emanuelli G. Studies on mechanisms involved in hypoglycaemia-induced platelet activation. Diabetes 1986;35:818–825

21. Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest 2005;115:2069–2072

22. Dotson S, Freeman R, Failing HJ, Adler GK. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care 2008;31:1222–1223

23. Razavi Nematollahi L, Kitabchi AE, Kitabchi AE, Stentz FB, Wan JY, Larjani BA, Tehrani MM, Gozashti MH, Omidi Far K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism Clinical and Experimental 2009;58:443–448

24. Dandona P. Endothelium, inflammation, and diabetes. Curr Diab Rep 2002;2:311–315

25. Dandona P, Aljada A, Mohanty P, Ghanim H, Bandypadhyay A, Chaudhuri A. Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 2003;26:3310–3314